Breast Cancer Specialist in Guatemala
Breast cancer is treatable. The right treatment depends on your tumor's biology.
Not all breast cancers are the same. HER2-positive, triple negative, and luminal are different diseases with different treatments. The molecular subtype changes everything.
When should you consult Dr. Reynoso?
You were diagnosed with breast cancer and want a complete oncologic evaluation before starting treatment
You have your biopsy result but don't know the next step
Your diagnosis doesn't include molecular markers — ER, PR, HER2, Ki67
You're already in treatment and want to confirm it's correct for your subtype
Your tumor progressed on current treatment and you're looking for options
You want an independent second opinion before deciding
⚡ Consultations Monday, Tuesday, and Thursday | By appointment only
90%+
5-year survival rate for localized breast cancer with the right treatment
3
distinct molecular subtypes — each with a different treatment protocol
8+
years treating breast cancer at every stage in Guatemala
Q600
initial consultation with complete case review and treatment plan
It's not one cancer. It's several.
Breast cancer is classified into molecular subtypes based on the presence of hormone receptors and HER2. Luminal A and B, HER2-positive, and triple negative have completely different behaviors, prognoses, and treatments. A stage II triple negative breast cancer isn't treated the same way as a luminal one at the same stage.
That's why the first step isn't starting chemotherapy — it's knowing exactly which subtype it is, what stage it's at, and what the complete molecular profile shows. Without that information, any treatment is a guess. The first consultation with Dr. Reynoso starts by reviewing exactly that.
“Before talking about treatment, I need to know which breast cancer subtype this is. ER, PR, HER2, Ki67 — those four markers completely change the plan. Without them, there's no correct treatment.”—Dr. Giovanni Reynoso
Symptoms that require an oncologic evaluation.
Breast cancer is often detected through self-exam or mammography before producing obvious symptoms. When symptoms do appear, oncologic evaluation shouldn't be delayed.
Lump or mass in the breast
A palpable lump in the breast or armpit, of any size. Not every lump is malignant, but all require evaluation with imaging and, when indicated, a biopsy.
Changes in breast skin
Redness, thickening, an orange-peel appearance, or skin retraction. May indicate inflammatory breast cancer — an aggressive form requiring urgent evaluation.
Nipple changes
Nipple retraction, spontaneous discharge — especially if unilateral, clear, or bloody — or changes in the appearance of the areola.
Palpable underarm lymph nodes
Palpable lumps in the armpit without an active infection. May indicate lymphatic spread of the tumor — this changes the stage and the treatment plan.
Persistent bone pain
In patients with a prior breast cancer diagnosis, new or worsening bone pain should be evaluated to rule out bone metastasis.
Findings on mammogram or ultrasound
A BIRADS 4 or 5 finding on imaging — a spiculated mass, clustered calcifications, architectural distortion. Always requires a biopsy for histological diagnosis.
New shortness of breath or chest pain
In patients with a history of breast cancer, new respiratory symptoms without an obvious cause should be evaluated to rule out lung or pleural metastasis.
Biopsy result without a clear plan
Having a biopsy result without an oncology consultation to explain what it means and what the next step is — that's also a sign it's time to see a specialist.
Do you identify with any of these?
A first one-hour consultation is enough to begin your workup and, if applicable, reach a clear diagnosis
When the first treatment wasn't enough.
Progression or relapse in breast cancer doesn't close off treatment options. Metastatic breast cancer has multiple available lines of treatment — and choosing the right one depends on the subtype, prior treatments received, and the molecular profile at the time of progression.
HER2-positive breast cancer in progression
After trastuzumab and pertuzumab, there are powerful second-line options — trastuzumab deruxtecan (T-DXd), tucatinib, lapatinib. The right choice depends on prior treatments and the status of the central nervous system.
Refractory triple negative breast cancer
In triple negative cases with PD-L1 expression, immunotherapy with pembrolizumab or atezolizumab may be an option. In tumors with BRCA mutations, PARP inhibitors (olaparib, talazoparib) offer significant responses.
Hormone therapy-resistant luminal breast cancer
Resistance to hormone therapy in metastatic luminal cancer can be managed with CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib), PI3K inhibitors (alpelisib for PIK3CA mutations), or switching endocrine agents.
“Progression doesn't mean the options have run out. In metastatic breast cancer there are multiple lines of treatment — the key is knowing which one fits that subtype and that moment.”—Dr. Giovanni Reynoso
How breast cancer is evaluated in consultation
A complete oncologic diagnosis of breast cancer goes beyond the biopsy. It requires knowing the molecular subtype, the stage, and the full clinical context before designing the treatment plan.
Complete case review
Detailed medical history, review of mammogram, ultrasound, MRI when applicable, biopsy result, and any prior treatment received.
Complete molecular profile
Review of estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki67 proliferation index. If not yet performed, they're requested on available biopsy tissue. These four markers determine the subtype and the treatment.
Staging
Assessment of disease extent — lymph nodes, bone, lung, liver. In localized disease, staging guides the treatment sequence — neoadjuvant versus adjuvant.
Evaluation of additional biomarkers when applicable
BRCA mutations in triple negative and metastatic luminal cases, PIK3CA in resistant luminal cases, PD-L1 in triple negative. These determine access to specific targeted therapies.
Multidisciplinary coordination
In localized and locally advanced disease, the treatment plan is designed in coordination with surgical oncology and radiotherapy. Dr. Reynoso defines the systemic component — chemotherapy, hormone therapy, anti-HER2 therapy.
Personalized treatment plan
With the subtype, stage, and full clinical context in hand, the protocol is designed — neoadjuvant, adjuvant, or palliative — with the right agents for that specific case.
Why consult Dr. Reynoso for breast cancer?
Treatment based on molecular subtype, not on the name of the cancer
Dr. Reynoso doesn't treat “breast cancer” generically. He treats luminal, HER2-positive, and triple negative tumors — with the specific protocols each subtype requires under ASCO and ESMO guidelines.
Member of ASCO and ESMO — the most up-to-date protocols
Breast cancer treatment guidelines are updated every year. Dr. Reynoso applies the most recent protocols from the world's two most influential oncology societies.
Management of advanced and resistant disease
Metastatic breast cancer, progression on first-line treatment, resistance to hormone therapy — Dr. Reynoso evaluates available second- and third-line options with up-to-date judgment, without prematurely ruling anything out.
Real time to understand your case
A full hour per consultation — to review your studies, explain the diagnosis, answer questions from the patient and family, and build a plan that makes sense for the person who will live it.
Treatment based on molecular subtype, not on the name of the cancer
Dr. Reynoso doesn't treat “breast cancer” generically. He treats luminal, HER2-positive, and triple negative tumors — with the specific protocols each subtype requires under ASCO and ESMO guidelines.
Member of ASCO and ESMO — the most up-to-date protocols
Breast cancer treatment guidelines are updated every year. Dr. Reynoso applies the most recent protocols from the world's two most influential oncology societies.
Management of advanced and resistant disease
Metastatic breast cancer, progression on first-line treatment, resistance to hormone therapy — Dr. Reynoso evaluates available second- and third-line options with up-to-date judgment, without prematurely ruling anything out.
Real time to understand your case
A full hour per consultation — to review your studies, explain the diagnosis, answer questions from the patient and family, and build a plan that makes sense for the person who will live it.
Received a cancer diagnosis? The next step is a consultation.
First visit, second opinion, or oncologic follow-up — you deserve an oncologist who explains everything.
Medical Oncology in Guatemala City
Dr. Giovanni Reynoso - Oncólogo
Edificio Spazio, 15 avenida y 5 calle 5-50, Vista Hermosa III, Zona 15. Nivel 10, Oficina 10-01Bonanova Health, private hospital specializing in cancer in Zona 15
Office Hours
Monday to Tuesday from 4:00 PM to 6:00 PM Thursday from 3:00 PM to 5:00 PM
Emergency Care
Dr. Reynoso does not handle emergencies. For oncologic emergencies, go to the nearest hospital.
Coverage Areas
Guatemala City
- • Zona 15, Vista Hermosa I, II, and III
- • Zona 10, 14, 16
- • Zona 9, 13
- • Carretera a El Salvador
Metropolitan Area
- • Mixco
- • Villa Nueva
- • Santa Catarina Pinula
- • San Cristóbal
Departmental Coverage
- • All departments of Guatemala
- • Patients traveling from other parts of the country
- • Zacapa, Chiquimula, Izabal, San Marcos, Petén
International Coverage
- • El Salvador
- • Belize
- • Honduras
- • Costa Rica
Common questions, clear answers
Still have questions? Let’s talk directly on WhatsApp for personalized answers.